The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1513
Drug Interaction: Dabigatran (Pradaxa) and Statins
The full article is available to subscribers Subscriber Login   

The results of a recently published study suggest that taking the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa) with either simvastatin (Zocor, and others) or lovastatin (Altoprev, and others) increases the risk of major hemorrhage.1

POSSIBLE MECHANISMS — The mechanism for this potential interaction has not been established. Dabigatran etexilate is a substrate of the transporter P-glycoprotein (P-gp); drugs that inhibit P-gp could increase dabigatran serum concentrations and the risk of bleeding.2 In in vitro studies, simvastatin and lovastatin have been shown to inhibit P-gp3; however, limited data from in vivo studies suggest simvastatin and lovastatin have little to no effect on serum concentrations of P-gp substrates such as digoxin. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Drug Interaction: Dabigatran (Pradaxa) and Statins
Article code: 1513e
 Electronic, downloadable article - $25